of M. morganii, was detected in two isolates of E. coli. DHA-1 is an inducible plasmid-mediated AmpC b-lactamase whose emergence raises concerns because the mortality of patients infected with organisms that produce DHA-1 has been shown to be higher than that of patients infected with organisms that produce CMY-1.
*Corresponding author. Tel: þ82-2-380-1478; Fax: þ82-2-380-1550; E-mail: yslee07@nih.go.kr Sir, Resistance to macrolide, lincosamide and streptogramin B (MLS B ) antibiotics in Staphylococcus spp. is mediated by a methylase encoded by erythromycin ribosome methylation (erm) genes or ATP transporter efflux pumps encoded by the msr or mef genes. The methylation of the 50S ribosomal subunit by erm gene products causes constitutive or inducible resistance to MLS B antibiotics. Constitutively resistant MLS B (MLS B c) strains and inducibly resistant MLS B (MLS B i) strains express erm genes, erm(A) or/and erm(C). In this study, we investigated and characterized the constitutive and inducible resistance, and the susceptibility to clindamycin of Staphylococcus aureus isolated from non-tertiary hospitals.
We collected 508 S. aureus strains from 157 hospitals nationwide from January to June 2005 in Korea. Antimicrobial susceptibility to oxacillin, erythromycin, clindamycin and quinupristin/ dalfopristin and the MICs were evaluated according to the guidelines of the CLSI. Of the 508 S. aureus isolates, 46.1% (234 isolates) were resistant to oxacillin, 55.1% (280 isolates) were resistant to erythromycin, which comprised 98.3% (230/234) methicillin-resistant S. aureus (MRSA) strains and 18.2% (50/274) methicillin-susceptible S. aureus (MSSA) strains, and 37.4% (190 isolates) were resistant to clindamycin. No strains were susceptible to erythromycin and resistant to clindamycin. One hundred and eighty-six MRSA (80.9%) and four MSSA (8.0%) were MLS B c (resistant to erythromycin and clindamycin; Table 1 ). D-test according to Steward's method was used for isolates with erythromycin resistance and clindamycin susceptibility. The MLS B resistance genes, erm(A), erm(B), erm(C), msr(A), msr(B) and mef, were detected using a PCR method. 2 erm(A) was detected in 250 strains, erm(C) in 14 strains, erm(B) in 1 strain, msr(A) in 3 strains, erm(A) and erm(C) in 2 strains, erm(A) and msr(A) in 3 strains and no genes in 7 strains.
Most MLS B c and MLS B i strains carried the erm(A) or erm(C) gene ( Table 1) . The erm(A) gene (in 250 isolates) was detected far more frequently than erm(C) (in 14 strains). However, the erm(C) gene was distributed more frequently in MLS B i strains (12 isolates) than in MLS B c strains (2 isolates). Using OLIGO primers designed by Arthur et al., 3 the PCR products were detected in three MLS B c or MLS B i strains lacking erm(A), erm(B) or erm(C). It was possible that the three strains carry an erm gene besides erm(A), erm(B) or erm(C). msr(A) was detected in one MRSA isolate and five MSSA isolates, three MLS B i isolates carried msr(A) together with erm(A) and three MLS B s contained only msr(A).
We also found msr(A) in three of seven MLS B s isolates but did not detect the msr(A) gene in four MLS B s strains. To determine whether the four MLS B s isolates carried the msr(A) gene, Southern hybridization was performed by the Amersham ECL Direct Nucleic Acid Labeling and Detection system (Amersham, GE Healthcare Life Science, USA), but no fragments were detected (data not shown). Also, any resistance genes encoding ATP transporter efflux pumps [msr(B), msr(C) and msr(D)], mef(A/E) genes and the phosphorylase mph(C) gene were not detected in the four strains (data not shown).
The MICs of erythromycin for MLS B c and MLS B i isolates were 256 mg/L, with the exception of one strain with an MIC of 8 mg/L. The MICs of erythromycin for the MLS B s strains were 4, 8 or 64 mg/L. The MICs of clindamycin for clindamycin-susceptible and clindamycin-resistant strains, determined by agar dilution, were 1 and 64 mg/L, respectively (Table 1) .
It has been reported that MLS B c and MLS B i isolates in Staphylococcus carry erm(A), erm(B) or erm(C), and at times erm together with msr(A), but MLS B s carry the msr(A) gene. We propose that MICs of erythromycin of 4 -64 mg/L are insufficient to induce resistance to clindamycin, and the erm genes were expressed at high concentrations of erythromycin and the msr(A) gene at low concentrations. If the msr and erm genes are detected together, the erm gene may be expressed more rapidly than the msr gene and the phenotype of the strain may be MLS B c or MLS B i.
In conclusion, the erythromycin resistance rate in S. aureus was high at 55.1%, and 99.6% of erythromycin-resistant MRSA and 88.0% of MSSA strains were MLS B c or MLS B i. Therefore, the treatment of infections caused by erythromycin-resistant S. aureus with clindamycin in non-tertiary hospitals is not effective. Table 1 Sir, Burkholderia pseudomallei, a Gram-negative bacterium, causes a disease called melioidosis in humans and animals. 1 The bacterium is a soil organism found mainly in Southeast Asia and Northern Australia. Antibiotics currently recommended for therapy of melioidosis are ceftazidime, imipenem, meropenem, amoxicillin/clavulanate, trimethoprim/sulfamethoxazole, doxycycline and chloramphenicol. 1 A development of resistance of B. pseudomallei to the aforementioned antibiotics has been recognized; 2, 3 hence, a search for new agents effective against B. pseudomallei is needed.
Ceftobiprole is a novel parenteral cephalosporin whose broad spectrum of activity includes most clinically important Gram-positive and Gram-negative bacteria. 4 One hundred and fifteen strains of ceftazidime-susceptible B. pseudomallei from different infected patients were selected from our collection. All strains were identified as B. pseudomallei by API 20NE (bioMérieux, France). In vitro susceptibility was determined by Kirby-Bauer disc diffusion for all 115 strains and Etest for 5 randomly chosen strains. Paper discs containing 30 mg ceftobiprole per disc (MASTDISC) and Etest strips of ceftobiprole at concentrations of 0.016 -256 mg/L were provided by Janssen-Cilag (Thailand). The disc diffusion test was repeated for six strains of B. pseudomallei in order to determine the reproducibility of the test. The methodology for susceptibility testing was performed by direct colony suspension according to guidelines suggested by the CLSI. The inhibition zone diameter of ceftobiprole against P. aeruginosa ATCC 27853 was within the reference limits. The distribution of inhibition zone diameters of ceftobiprole against B. pseudomallei is shown in Table 1 . Inhibition zone diameters of 20, 17 -19 and 16 mm were observed in 46 (40%), 55 (47.8%) and 14 (12.2%) strains, respectively. Four strains of B. pseudomallei with inhibition zone diameters of 15 -19 mm on the initial disc diffusion test had identical inhibition zone diameters on the second test. Another two strains with an inhibition zone diameter of .20 mm had 1 mm difference in inhibition zone diameter on the second test, but the inhibition zone diameters from both tests were still within susceptible values. Four B. pseudomallei strains with an inhibition zone diameter of 17 -19 mm had MICs of ceftobiprole of 6 -8 mg/L, whereas a strain with an inhibition zone diameter of 16 mm had an MIC of 16 mg/L.
Our findings indicate that the in vitro activity of ceftobiprole against B. pseudomallei determined by Kirby-Bauer disc diffusion is reproducible and correlates with that determined by Etest. Ceftobiprole has less in vitro activity than ceftazidime against B. pseudomallei, and only 40% of B. pseudomallei strains are susceptible to ceftobiprole. 
